Chimerix Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chimerix stock.
View analyst ratings for Chimerix or view top-rated stocks.

Wall Street analysts have given Chimerix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chimerix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Chimerix is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Chimerix.

Chimerix, Inc. (NASDAQ:CMRX) released its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.73. Chimerix had a negative trailing twelve-month return on equity of 36.57% and a negative net margin of 321.31%.
View Chimerix's earnings history.

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CMRX stock has increased by 466.0% and is now trading at $8.15.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 12 month target prices for Chimerix's stock. Their forecasts range from $14.00 to $21.00. On average, they anticipate Chimerix's share price to reach $18.80 in the next twelve months. This suggests a possible upside of 130.7% from the stock's current price.
View analysts' price targets for Chimerix or view top-rated stocks among Wall Street analysts.

Some companies that are related to Chimerix include Taro Pharmaceutical Industries (TARO), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), MorphoSys (MOR), Insmed (INSM), Rocket Pharmaceuticals (RCKT), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), Prestige Consumer Healthcare (PBH), Zentalis Pharmaceuticals (ZNTL), Cryoport (CYRX), OPKO Health (OPK), Organogenesis (ORGO), Axsome Therapeutics (AXSM) and Xencor (XNCR).
View all of CMRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.29%), Renaissance Technologies LLC (3.29%), Geode Capital Management LLC (1.45%), New Leaf Venture Partners L.L.C. (1.42%), Northern Trust Corp (0.71%) and Acadian Asset Management LLC (0.38%). Company insiders that own Chimerix stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix.

CMRX stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, New Leaf Venture Partners L.L.C., JPMorgan Chase & Co., Renaissance Technologies LLC, GSA Capital Partners LLP, Alliancebernstein L.P., Vanguard Capital Wealth Advisors, and Bank Julius Baer & Co. Ltd Zurich. Company insiders that have sold Chimerix company stock in the last year include David Jakeman, and Martha J Demski.
View insider buying and selling activity for Chimerix or view top insider-selling stocks.

CMRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, UBS Group AG, Russell Investments Group Ltd., Citigroup Inc., Rafferty Asset Management LLC, Northern Trust Corp, and Barclays PLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix or or view top insider-buying stocks.

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CMRX stock can currently be purchased for approximately $8.15.

Chimerix has a market capitalization of $702.62 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

Chimerix employs 54 workers across the globe.

The official website for Chimerix is www.chimerix.com.

Chimerix is headquartered at 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]